Format

Send to

Choose Destination
Cell. 2014 Nov 6;159(4):721-6. doi: 10.1016/j.cell.2014.10.016.

Lessons from a failed γ-secretase Alzheimer trial.

Author information

1
VIB Center for the Biology of Disease, Leuven 3000, Belgium; KU Leuven Center for Human Genetics and Leuven Institute for Neurodegenerative disorders (LIND), University of Leuven 3000, Belgium; UCL Institute of Neurology, University College London, Queen Square, London WC1N 1PJ, UK. Electronic address: bart.destrooper@cme.vib-kuleuven.be.

Abstract

γ-Secretase proteases have been associated with pathology in Alzheimer disease (AD), but we are just beginning to understand their basic mechanisms and physiological roles. A negative drug trial with a broad spectrum γ-secretase inhibitor in AD patients has severely dampened enthusiasm for the potential of pursuing γ-secretase research therapeutically. This pessimism is unwarranted: analysis of available information presented here demonstrates significant confounds for interpreting the outcome of the trial and argues that the major lessons pertain to broad knowledge gaps that are imperative to fill.

PMID:
25417150
DOI:
10.1016/j.cell.2014.10.016
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center